Compare QXL & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QXL | LONA |
|---|---|---|
| Founded | N/A | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.6M | 71.2M |
| IPO Year | 2015 | 2020 |
| Metric | QXL | LONA |
|---|---|---|
| Price | $5.60 | $6.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 62.4K | 38.3K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $26,941,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $57.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.05 | $4.21 |
| 52 Week High | $7.70 | $14.21 |
| Indicator | QXL | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 64.19 | 47.88 |
| Support Level | $4.09 | $6.86 |
| Resistance Level | N/A | $8.57 |
| Average True Range (ATR) | 0.35 | 0.66 |
| MACD | 0.13 | -0.04 |
| Stochastic Oscillator | 74.87 | 37.79 |
Quantum X Labs Inc is an Israel-based multi-disciplinary quantum technology company focused on the research, development, and commercialization of quantum technologies and intellectual property. The company operates across a broad range of domains, including quantum computing, quantum sensing, navigation systems, atomic clocks, and quantum algorithms, with applications spanning defense, aerospace, transportation, cybersecurity, and life sciences.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.